Lead Product(s) : Dipivefrin
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Aquestive has submitted multiple U.S. and foreign patent applications that cover the technology and formulations for its two prodrug candidates, AQST-108 and AQST-109. If granted, Aquestive anticipates patent protection for both drug candidates through a...
Brand Name : AQST-108
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 25, 2021
Lead Product(s) : Dipivefrin
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?